Corporate Presentation

Biophytis is a pioneering biotechnology company focused on developing transformative therapies that impact longevity, anchored by its lead asset BIO101. This oral small molecule is a potential first-in-class drug candidate in the multi-billion dollar markets of sarcopenia and mobility impairment in obesity. The company’s program in sarcopenia (SARA) is the world’s most advanced clinical program, preparing for a pivotal Phase 3 study. Biophytis is listed on Euronext (ALBPS) and the US market (OTC).